Suppr超能文献

新型生物可降解支架在胆胰疾病中的应用:一项前瞻性多中心可行性研究。

A new biodegradable stent in bilio-pancreatic diseases: a prospective multi-center feasibility study.

机构信息

Gastroenterology, Hôpital Européen Georges Pompidou, France.

Asian Institute of Gastroenterology. AIG Hospitals.

出版信息

Rev Esp Enferm Dig. 2022 Sep;114(9):529-533. doi: 10.17235/reed.2022.8451/2021.

Abstract

INTRODUCTION

biodegradable stents of various designs are reportedly used in pancreato-biliary conditions with promising results. Their major advantage is the avoidance of repeat endoscopic procedure for stent removal, thereby reducing overall costs and endoscopic retrograde cholangiopancreatography (ERCP) associated adverse events. The aim of the study was to evaluate the feasibility and safety of a new biodegradable stent in patients with pancreato-biliary diseases.

METHODS

a prospective multicenter pilot study was performed. All consecutive patients ≥ 18 years old who underwent biliary or pancreatic stenting using the new biodegradable Archimedes stent were included in the study. There were three biodegradation profiles. Technical and clinical success and feasibility and safety were assessed during a pre-established follow-up schedule.

RESULTS

fifty-three patients (mean age: 48.54 ± 19.29, 66 % male) with biliary (n = 29, 54.7 %) or pancreatic (n = 24, 45.3 %) indications were included. The distribution of stents used according to degradation properties were as follows: fast (n = 11, 20.8 %), medium (n = 16, 30.2 %) and slow (n = 26, 49.1 %). The technical and clinical success were 100 % and 77.8 %, respectively. Thirty-five patients were followed for a median of 26 weeks (range: 4-56, 66 %). There were nine procedure-related adverse events (17 %), all mild, including one uneventful stent-related event (external migration).

CONCLUSION

the biodegradable Archimedes stent placement is feasible and safe in pancreato-biliary diseases.

摘要

简介

各种设计的生物可降解支架据称可用于胰胆疾病,具有良好的效果。其主要优势在于避免了因取出支架而需重复进行内镜操作,从而降低了总体成本和内镜逆行胰胆管造影术(ERCP)相关的不良事件发生率。本研究旨在评估新型生物可降解支架在胰胆疾病患者中的应用的可行性和安全性。

方法

进行了一项前瞻性多中心试点研究。所有接受新型生物可降解 Archimedes 支架进行胆道或胰腺支架置入的年龄≥18 岁的连续患者均纳入研究。支架有三种降解特性。在预先确定的随访计划中评估技术和临床成功率以及可行性和安全性。

结果

共纳入 53 例(平均年龄:48.54±19.29 岁,66%为男性)有胆道(n=29,54.7%)或胰腺(n=24,45.3%)适应证的患者。根据降解特性使用的支架分布情况如下:快速降解(n=11,20.8%)、中速降解(n=16,30.2%)和慢速降解(n=26,49.1%)。技术和临床成功率分别为 100%和 77.8%。35 例患者的中位随访时间为 26 周(范围:4-56,66%)。有 9 例(17%)与操作相关的不良事件,均为轻度,包括 1 例无并发症的支架相关不良事件(外移)。

结论

在胰胆疾病中,生物可降解 Archimedes 支架置入是可行和安全的。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验